Abstract: Disclosed herein is a method comprising imaging a network section through which flow occurs; where the flow is selected from a group consisting of fluid, electrons, protons, neutrons and holes; partitioning the image into sub-regions based on metabolic need and function; where each region comprises one or more sources and one or more sinks; where the flow emanates from the source and exits into the sinks; performing a Delaunay triangulation tessellation on one or more sub-regions by connecting one or more sources and one or more sinks; where the Delaunay triangulations maximize the minimum angle of all the angles of the triangles in the triangulation; generating a Voronoi diagram from the Delaunay triangulation by subdividing the sub-regions into Voronoi cells, where each Voronoi cell contains exactly one sink or one source; and where the intersections of Voronoi cells are Voronoi cell vertices; locating a sink endpoint centroid; connecting a source to a nearest Voronoi cell vertex; connecting at least one si

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Abstract: Devices and methods for testing cement include: a pressure vessel with a sample container inside an interior working volume of the pressure vessel, the pressure vessel configured to supply a first pressurized fluid to control a pore pressure of a cement sample and to supply a second pressurized fluid to lateral exterior surfaces of the sample container to provide a confining pressure that can be different than the pore pressure.

Abstract: Disclosed herein is a method comprising a method comprising imaging a network section through which flow occurs; where the flow is selected from a group consisting of fluid, electrons, protons, neutrons and holes; partitioning the image into sub-regions based on metabolic need and function; where each region comprises one or more sources and one or more sinks; where the flow emanates from the source and exits into the sinks; generating a Voronoi diagram from the Delaunay triangulation by subdividing the sub-regions into Voronoi cells, where each Voronoi cell contains exactly one sink or one source; and where the intersections of Voronoi cells are Voronoi cell vertices; calculating a flow rate in each Voronoi cell; and according a color to Voronoi cells based on their flow rates; where Voronoi cells having similar rates are accorded similar colors.

Abstract: Disclosed herein is a method comprising imaging a network section through which flow occurs; where the flow is selected from a group consisting of fluid, electrons, protons, neutrons and holes; partitioning the image into sub-regions based on metabolic need and function; where each region comprises one or more sources and one or more sinks; where the flow emanates from the source and exits into the sinks; performing a Delaunay triangulation tessellation on one or more sub-regions by connecting one or more sources and one or more sinks; where the Delaunay triangulations maximize the minimum angle of all the angles of the triangles in the triangulation; generating a Voronoi diagram from the Delaunay triangulation by subdividing the sub-regions into Voronoi cells, where each Voronoi cell contains exactly one sink or one source; and where the intersections of Voronoi cells are Voronoi cell vertices; locating a sink endpoint centroid; connecting a source to a nearest Voronoi cell vertex; connecting at least one si

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: Disclosed herein is a method for designing an organ for use in a body of a living being comprising identifying a fluid transport demand of an organ; where the fluid transport demand is the amount of fluid used by the organ to sustain itself and to sustain utility in other organs around it; and where the organ comprises a flow system comprising a network of vessels; determining a spatial density of zones of need in the organ based on a density of normal healthy tissues in the organ; identifying a nature of the flow system; and using constructal principle analysis to generate a design of the organ. Disclosed herein too is an organ manufactured by the aforementioned method.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated.

Abstract: The present invention is an aqueous pharmaceutical composition that includes an ionized therapeutic agent, an ionic component and guar gum. The guar gum is present in the composition a concentration sufficient to limit interactions between the ionized therapeutic agent and the ionic component thereby imparting stability to the composition. The composition is preferably at or near physiologic pH. The aqueous pharmaceutical composition has been found particularly useful as an aqueous ophthalmic, otic or nasal composition. The pharmaceutical composition, due to its characteristics, is particularly suitable as an ophthalmic composition.

Abstract: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.

Abstract: Devices and methods for testing cement include: a pressure vessel with a sample container inside an interior working volume of the pressure vessel, the pressure vessel configured to supply a first pressurized fluid to control a pore pressure of a cement sample and to supply a second pressurized fluid to lateral exterior surfaces of the sample container to provide a confining pressure that can be different than the pore pressure.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: Devices and methods for testing cement include: a pressure vessel with a sample container inside an interior working volume of the pressure vessel, the pressure vessel configured to supply a first pressurized fluid to control a pore pressure of a cement sample and to supply a second pressurized fluid to lateral exterior surfaces of the sample container to provide a confining pressure that can be different than the pore pressure.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described.